We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
In its upcoming report, Ionis Pharmaceuticals (IONS - Free Report) is predicted by Wall Street analysts to post quarterly loss of $1.12 per share, reflecting a decline of 1766.7% compared to the same period last year. Revenues are forecasted to be $137.47 million, representing a year-over-year decrease of 57.7%.
Over the last 30 days, there has been an upward revision of 3.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Ionis Pharmaceuticals metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenue- Commercial Revenue- Spinraza royalties' reaching $60.73 million. The estimate indicates a year-over-year change of -2%.
Analysts predict that the 'Revenue- Commercial Revenue- Licensing and royalty revenue' will reach $5.23 million. The estimate indicates a year-over-year change of -34.7%.
The collective assessment of analysts points to an estimated 'Revenue- Total commercial revenue' of $80.55 million. The estimate indicates a change of +2% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Commercial Revenue- Tegsedi and Waylivra revenue, net' should come in at $7.06 million. The estimate indicates a change of -21.6% from the prior-year quarter.
The average prediction of analysts places 'Revenue- R&D Revenue- Collaborative agreement revenue' at $43.79 million. The estimate indicates a year-over-year change of -75.5%.
Shares of Ionis Pharmaceuticals have experienced a change of -1.2% in the past month compared to the +4.7% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), IONS is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
In its upcoming report, Ionis Pharmaceuticals (IONS - Free Report) is predicted by Wall Street analysts to post quarterly loss of $1.12 per share, reflecting a decline of 1766.7% compared to the same period last year. Revenues are forecasted to be $137.47 million, representing a year-over-year decrease of 57.7%.
Over the last 30 days, there has been an upward revision of 3.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Ionis Pharmaceuticals metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenue- Commercial Revenue- Spinraza royalties' reaching $60.73 million. The estimate indicates a year-over-year change of -2%.
Analysts predict that the 'Revenue- Commercial Revenue- Licensing and royalty revenue' will reach $5.23 million. The estimate indicates a year-over-year change of -34.7%.
The collective assessment of analysts points to an estimated 'Revenue- Total commercial revenue' of $80.55 million. The estimate indicates a change of +2% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue- Commercial Revenue- Tegsedi and Waylivra revenue, net' should come in at $7.06 million. The estimate indicates a change of -21.6% from the prior-year quarter.
The average prediction of analysts places 'Revenue- R&D Revenue- Collaborative agreement revenue' at $43.79 million. The estimate indicates a year-over-year change of -75.5%.
View all Key Company Metrics for Ionis Pharmaceuticals here>>>
Shares of Ionis Pharmaceuticals have experienced a change of -1.2% in the past month compared to the +4.7% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), IONS is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>